- 甲磺酸溴隐亭；CB-154
货号： abs813529
| 货号-规格 | 货期 | 价格 | 数量 |
| abs813529-50mg | 现货 | ￥667.00 | - + |
| abs813529-100mg | 现货 | ￥909.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | Bromocriptine, an ergoline derivative, is a dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease (PD), hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes. | |
| 纯度 | >98% | |
| 储存/保存方法 | store at -20℃ for one year（Powder）；
in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months. | |
| 基本信息 | ||
| 别名 | 甲磺酸溴隐亭；CB-154 | |
| 外观 | white solid | |
| 可溶性/溶解性 | DMSO : ≥ 30 mg/mL | |
| 生物活性 | ||
| 靶点 | Dopamine Receptor | |
| In vitro(体外研究) | Bromocriptine stimulates -GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC50 of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC50=10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC50>100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC50 value for the interaction of 1.69 μM. | |
| In vivo(体内研究) | Bromocriptine mesylate (2 mg/kg, i.p.) is administered for 7 days in groups of mice in forced swimming test (FST) and tail suspension test (TST). Bromocriptine group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produces significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine treatment group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) shows significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intracisternal administration of Bromocriptine decreases significantly the static mechanical allodynia (SMA) score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg and 1 mg/kg) decrease in pain scores in CCI-IoN group when compared to sham and its effect lasted for 6 h. The highest dose induces the highest score decrease (P. | |
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要提问”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
